Septerna FY2025 EPS Forecast Lowered by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has revised Septerna's FY2025 earnings per share estimate significantly lower, from ($0.14) to ($1.90), while also projecting ($2.15) EPS for FY2026.
• Recently, Septerna reported a quarterly loss of ($0.56) per share, missing analysts' forecasts by ($0.51) and generating revenue of only $0.12 million compared to expected revenue of $22.50 million.
• Despite the negative earnings outlook, Septerna maintains an "Overweight" rating from Cantor Fitzgerald and has a consensus rating of "Moderate Buy" with a target price of $26.75.

Septerna, Inc. (NASDAQ:SEPN - Free Report) - Cantor Fitzgerald decreased their FY2025 EPS estimates for shares of Septerna in a research note issued to investors on Tuesday, August 12th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will earn ($1.90) per share for the year, down from their previous estimate of ($0.14). Cantor Fitzgerald has a "Overweight" rating and a $25.00 price objective on the stock. The consensus estimate for Septerna's current full-year earnings is ($7.11) per share. Cantor Fitzgerald also issued estimates for Septerna's FY2026 earnings at ($2.15) EPS.

Septerna (NASDAQ:SEPN - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.51). Septerna had a negative net margin of 12,053.03% and a negative return on equity of 31.52%. The company had revenue of $0.12 million during the quarter, compared to the consensus estimate of $22.50 million.

A number of other equities research analysts have also recently issued reports on SEPN. Wells Fargo & Company increased their target price on shares of Septerna from $11.00 to $18.00 and gave the stock an "equal weight" rating in a research report on Friday, May 16th. Wall Street Zen lowered shares of Septerna from a "hold" rating to a "sell" rating in a research note on Saturday. Finally, HC Wainwright started coverage on shares of Septerna in a research report on Monday, June 23rd. They issued a "buy" rating and a $26.00 price objective on the stock. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Septerna presently has a consensus rating of "Moderate Buy" and an average price target of $26.75.

Septerna Stock Performance

Shares of NASDAQ:SEPN traded down $0.5090 during midday trading on Thursday, reaching $11.0810. 91,221 shares of the company's stock were exchanged, compared to its average volume of 683,598. The company's 50 day simple moving average is $11.55 and its two-hundred day simple moving average is $9.07. The firm has a market capitalization of $493.99 million and a PE ratio of -1.11. Septerna has a 12 month low of $4.17 and a 12 month high of $28.99.

Hedge Funds Weigh In On Septerna

Several institutional investors and hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC bought a new position in shares of Septerna in the fourth quarter worth about $25,000. Legal & General Group Plc bought a new stake in shares of Septerna during the 4th quarter worth $42,000. Summit Investment Advisors Inc. purchased a new position in Septerna during the 4th quarter valued at about $45,000. BNP Paribas Financial Markets purchased a new position in shares of Septerna during the fourth quarter worth about $52,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in Septerna in the first quarter worth approximately $49,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.